Well controlled Accumulations!!!! Beware everyone., page-8

Very true, and a measured position. PXS is in a good position though with a strong portfolio to develop and licence. Bronchitol could be a decent money spinner if/when rolled out in the US market. Surprised by the 2017 date for phase 2 (maybe they want to do a phase 1b next year before a phase 2) but in any case it's almost guaranteed that it will proceed and lead to at least another $40 million injection within 24 months, further swelling PXS's war chest.

Still think this one is undervalued - needs a roadshow to US and European investors, stale bulls (some of whom have posted their antipathy on HC) and large holder exiting are putting an artificial drag on the SP, look at some other pie in the sky biotech companies trading at $100 million plus with only a few quarters cash burn in the bank. PXS is near cash value, has a product with sales occurring and (hopefully) soon to grow and a host of other molecules, including one that is possibly very near to another exclusive deal... Definitely one to watch medium term.